Trinity Biotech's Deal Values Metabolomics Diagnostics With An Enterprise Value Of ~$1.3M With The Consideration Consisting Of Just Over 270,000 Trinity Biotech's ADS With The Balance Of Consideration Being In Cash And The Assumption Of Liabilities
Trinity Biotech's Deal Values Metabolomics Diagnostics With An Enterprise Value Of ~$1.3M With The Consideration Consisting Of Just Over 270,000 Trinity Biotech's ADS With The Balance Of Consideration Being In Cash And The Assumption Of Liabilities
DUBLIN, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has acquired privately held Metabolomics Diagnostics, an Irish deep-tech company, specialized in the development of novel biomarker-based diagnostic solutions for complex diseases. The deal values Metabolomics Diagnostics with an enterprise value of approximately $1.3 million with the consideration consisting of just over 270,000 Trinity Biotech plc's ADS with the balance of consideration being in cash and the assumption of liabilities.-Metabolomics Diagnostics, a deep-tech machine learning diagnostic platform developer, has developed an innovative test, PrePsia, to accurately predict the risk of preeclampsia in pregnant women-
-代謝組學診斷，一家深科技機器學習診斷平台開發商，已經開發出一項名爲PrePsia的創新測試，可以準確預測孕婦子癇前期的風險-
-The PrePsia test can predict preeclampsia risk as early as in the 12th week of pregnancy, allowing for early interventions to prevent serious health issues for mothers and their babies-
-PrePsia測試可以在懷孕第12周就能預測子癇前期風險，從而可以及早干預，預防母嬰嚴重健康問題-
-PrepSia will be commercialized in the U.S. market in 2025 through Trinity Biotech's New York-based Immco reference laboratory-
-PrepSia將通過總部位於紐約的trinity biotech旗下Immco參考實驗室，在2025年在美國市場上市-
DUBLIN, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has acquired privately held Metabolomics Diagnostics, an Irish deep-tech company, specialized in the development of novel biomarker-based diagnostic solutions for complex diseases. The deal values Metabolomics Diagnostics with an enterprise value of approximately $1.3 million with the consideration consisting of just over 270,000 Trinity Biotech plc's ADS with the balance of consideration being in cash and the assumption of liabilities.
都柏林，2024年9月24日（環球新聞社）- 納斯達克上市公司trinity biotech plc（納斯達克：TRIB）是一家專注於人類診斷和糖尿病管理解決方案的商業階段生物技術公司，包括可穿戴生物傳感器。今天宣佈收購愛爾蘭深科技公司Metabolomics Diagnostics，該公司專注於開發針對複雜疾病的新型生物標誌物診斷解決方案。這筆交易將Metabolomics Diagnostics的企業價值約爲130萬美元，其中包括超過27萬股trinity biotech plc的ADS作爲對價，剩餘對價爲現金和負債承擔。
This acquisition provides Trinity Biotech with a strategically important deep-tech platform of mass spectrometry combined with machine learning powered bioinformatics. Trinity Biotech will initially leverage its New York State-based Immco reference laboratory to rapidly commercialise the PrePsia test in the U.S. market, while examining the launch of this test in international markets. This technology platform represents another long-term growth driver alongside Trinity Biotech's continuous glucose monitoring (CGM) technology.
這次收購爲trinity biotech提供了一個戰略重要的深科技平台，結合了質譜與機器學習動力生物信息學。trinity biotech最初將利用位於紐約州的Immco參考實驗室迅速在美國市場上市PrePsia測試，同時考慮在國際市場推出這項測試。這一技術平台代表了trinity biotech連續葡萄糖監測（CGM）技術之外的另一個長期增長驅動因素。
譯文內容由第三人軟體翻譯。